Novozymes A/S (OTCMKTS:NVZMY - Get Free Report)'s stock price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $67.84 and traded as low as $62.33. Novozymes A/S shares last traded at $62.59, with a volume of 10,314 shares trading hands.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Berenberg Bank raised shares of Novozymes A/S to a "strong-buy" rating in a report on Tuesday, September 24th. Citigroup lowered Novozymes A/S from a "neutral" rating to a "sell" rating in a research report on Thursday, October 17th.
Check Out Our Latest Analysis on Novozymes A/S
Novozymes A/S Stock Down 0.3 %
The company has a 50 day moving average of $67.84 and a 200-day moving average of $63.60. The stock has a market capitalization of $29.24 billion, a P/E ratio of 39.61, a PEG ratio of 3.87 and a beta of 0.90.
Novozymes A/S Cuts Dividend
The business also recently declared a dividend, which was paid on Wednesday, September 18th. Investors of record on Monday, September 9th were issued a $0.1678 dividend. The ex-dividend date was Monday, September 9th. Novozymes A/S's dividend payout ratio (DPR) is 41.77%.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Read More
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.